Novel insights into disease modeling using induced pluripotent stem cells.

Induced pluripotent stem cell (iPSC) technology has great potential to establish novel therapeutic approaches in regenerative medicine and disease analysis. Although cell therapy using iPSC-derived cells still has many hurdles to overcome before clinical applications, disease analysis using patient-specific iPSCs may be of practical use in the near future. There are several reports that patient-specific iPSC-derived cells have recapitulated the apparent cellular phenotypes of a wide variety of diseases. Moreover, some studies revealed that it could be possible to discover effective new drugs and to clarify disease pathogenesis by examination of patient-specific iPSC-derived cells in vitro. We have recently reported that iPSCs can be a diagnostic tool in a patient with a novel mutation. For definitive diagnosis in a patient with long QT syndrome who had an uncharacterized genetic mutation, we succeeded in clarifying the patient's cellular electrophysiologic characteristics and the molecular mechanism underlying the disease phenotype through the multifaceted analyses of patient-specific iPSC-derived cardiomyocytes. In this review, we focus on the conceptual and practical issues in disease modeling using patient-specific iPSCs and discuss future directions in this research field.

[1]  S. Angulo,et al.  Retraction Notice to: Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons , 2014, Cell.

[2]  江頭 徹 Disease characterization using LQTS-specific induced pluripotent stem cells , 2013 .

[3]  Leslie Tung,et al.  Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. , 2012, Progress in biophysics and molecular biology.

[4]  Michael Glikson,et al.  Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.

[5]  S. Yamanaka,et al.  Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. , 2012, Blood.

[6]  C. Mummery,et al.  Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.

[7]  J. Mertens,et al.  Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. , 2012, The American journal of pathology.

[8]  K. Eggan,et al.  Erosion of dosage compensation impacts human iPSC disease modeling. , 2012, Cell stem cell.

[9]  Ofer Binah,et al.  Cardiomyocytes derived from human pluripotent stem cells for drug screening. , 2012, Pharmacology & therapeutics.

[10]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[11]  S. Orkin,et al.  A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome , 2012, Science Translational Medicine.

[12]  K. Nakao,et al.  Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation , 2012, Diabetologia.

[13]  Kristopher L. Nazor,et al.  Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.

[14]  Katriina Aalto-Setälä,et al.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.

[15]  H. Aburatani,et al.  Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. , 2010, Blood.

[16]  田中 智文,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes , 2012 .

[17]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[18]  Andrew P. Feinberg,et al.  Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells , 2011, Nature Biotechnology.

[19]  K. Kolaja,et al.  Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. , 2011, Toxicology and applied pharmacology.

[20]  D. Roden,et al.  Refining repolarization reserve. , 2011, Heart rhythm.

[21]  Gordon Keller,et al.  SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells , 2011, Nature Biotechnology.

[22]  Fred H. Gage,et al.  Modelling schizophrenia using human induced pluripotent stem cells , 2011, Nature.

[23]  G. Ananiev,et al.  Isogenic Pairs of Wild Type and Mutant Induced Pluripotent Stem Cell (iPSC) Lines from Rett Syndrome Patients as In Vitro Disease Model , 2011, PloS one.

[24]  Catherine Prescott The business of exploiting induced pluripotent stem cells , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[25]  Naoki Nishishita,et al.  Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors , 2011, Proceedings of the National Academy of Sciences.

[26]  S. Angulo,et al.  RETRACTED: Directed Conversion of Alzheimer's Disease Patient Skin Fibroblasts into Functional Neurons , 2011, Cell.

[27]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[28]  Susan Lindquist,et al.  Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.

[29]  Mitsugu Sekimoto,et al.  Reprogramming of mouse and human cells to pluripotency using mature microRNAs. , 2011, Cell stem cell.

[30]  T. Cech,et al.  Telomere shortening and loss of self-renewal in dyskeratosis congenita iPS cells , 2011, Nature.

[31]  Jun S. Song,et al.  Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells , 2011, Nature Cell Biology.

[32]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[33]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[34]  Blake Byers,et al.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. , 2011, Cell stem cell.

[35]  Divya Rajamohan,et al.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European heart journal.

[36]  Fumitaka Osakada,et al.  Modeling Retinal Degeneration Using Patient-Specific Induced Pluripotent Stem Cells , 2011, PloS one.

[37]  Gordon Keller,et al.  Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. , 2011, Cell stem cell.

[38]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[39]  Julie V. Harness,et al.  Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. , 2011, Cell stem cell.

[40]  J. Itskovitz‐Eldor,et al.  Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells , 2009, Journal of cellular and molecular medicine.

[41]  S. Lipton,et al.  Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. , 2011, Cell stem cell.

[42]  Andre Terzic,et al.  Induced pluripotent stem cells: developmental biology to regenerative medicine , 2010, Nature Reviews Cardiology.

[43]  A. Schnerch,et al.  Direct conversion of human fibroblasts to multilineage blood progenitors , 2010, Nature.

[44]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[45]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[46]  A. Meissner Epigenetic modifications in pluripotent and differentiated cells , 2010, Nature Biotechnology.

[47]  Ludovic Vallier,et al.  Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. , 2010, The Journal of clinical investigation.

[48]  K. Hochedlinger,et al.  Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells , 2010, Nature Biotechnology.

[49]  Shinsuke Yuasa,et al.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. , 2010, Cell stem cell.

[50]  Martin J. Aryee,et al.  Epigenetic memory in induced pluripotent stem cells , 2010, Nature.

[51]  James A Thomson,et al.  Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency , 2010, Proceedings of the National Academy of Sciences.

[52]  G. Daley,et al.  Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients , 2009, Nature.

[53]  E. Sasaki,et al.  Nongenetic method for purifying stem cell–derived cardiomyocytes , 2010, Nature Methods.

[54]  Robert Lanza,et al.  Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.

[55]  長船 健二 Marked differences in differentiation propensity among human embryonic stem cell lines , 2009 .

[56]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[57]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[58]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[59]  K. Hochedlinger,et al.  Epigenetic reprogramming and induced pluripotency , 2009, Development.

[60]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[61]  K. Hochedlinger,et al.  Guidelines and techniques for the generation of induced pluripotent stem cells. , 2008, Cell stem cell.

[62]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[63]  J. Byrne Generation of isogenic pluripotent stem cells. , 2008, Human molecular genetics.

[64]  Gordon Keller,et al.  Differentiation of Embryonic Stem Cells to Clinically Relevant Populations: Lessons from Embryonic Development , 2008, Cell.

[65]  Dan M. Roden,et al.  Clinical practice. Long-QT syndrome. , 2008, The New England journal of medicine.

[66]  Wojciech Zareba,et al.  Long QT Syndrome. , 1992, Current problems in cardiology.

[67]  B. Thiers Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[68]  S. Kattman,et al.  Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications. , 2008, Cold Spring Harbor symposia on quantitative biology.

[69]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[70]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[71]  J. Stockman Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice , 2007 .

[72]  D. Srivastava Making or Breaking the Heart: From Lineage Determination to Morphogenesis , 2006, Cell.

[73]  J. Ornato,et al.  ACC/AHA/ESC PRACTICE GUIDELINES ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death , 2006 .

[74]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[75]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[76]  M. Ackerman,et al.  Epinephrine QT Stress Testing in the Evaluation of Congenital Long-QT Syndrome: Diagnostic Accuracy of the Paradoxical QT Response , 2005, Circulation.

[77]  S. Priori,et al.  Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. , 2005, JAMA.

[78]  Michael J Ackerman,et al.  Drug-induced torsades de pointes: the evolving role of pharmacogenetics. , 2005, Heart rhythm.

[79]  Heribert Bohlen,et al.  Determination of electrical properties of ES cell-derived cardiomyocytes using MEAs. , 2004, Journal of electrocardiology.

[80]  S. Priori,et al.  Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. , 2004, Heart rhythm.

[81]  E. Marbán Cardiac channelopathies , 2020, Nature.

[82]  J. Barhanin,et al.  Novel mutations in KvLQT1 that affect Iks activation through interactions with Isk. , 2000, Cardiovascular research.